A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
James R. Berenson(American Society of Clinical Oncology), Howard Yeh(Covance (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Russell Mapes(Institute for Myeloma & Bone Cancer Research), Jeffrey Matous(Colorado Blood Cancer Institute), Blake Morrison(Millennium Engineering and Integration (United States))
Cited by 123
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
|Journal of Clinical Oncology|2000|383
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
|Nature Medicine|2023|239
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
|Supportive Care in Cancer|2013|182
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
|Journal of Bone and Mineral Research|2009|120